セッション情報

International Session(Oral)

第52回・2014年・横浜
International Session(Oral)
International Session 2
Anti Cancer Agent
開催回
第52回・2014年・横浜

ER alpha regulates Epithelial-mesenchymal transition in breast cancers through suppressing Bmi1 expression

演題番号 : ISO2-1

Zhang Guo-jun:1、Wei Xiao-Long:2、Bai Jing-Wen:1、Luo Xiang-Rong:1、Qiu Si-Qi:1

1:The Breast Center, The Affiliated Cancer Hospital of Shantou University Medical College, China、2:Department of Pathology, The Affiliated Cancer Hospital of Shantou University Medical College

ER alpha regulates Epithelial-mesenchymal transition in breast cancers through suppressing Bmi1 expression

Monocyte Chemoattractant Protein-1 Modulates Invasion and Apoptosis of PC-3M Prostate Cancer Cells Via Regulating Expression of VEGF, MMP9 and Caspase-3 Expression of VEGF, MMP9 and Caspase-3

演題番号 : ISO2-2

Shi Chaoling:1

1:Urology, FAW General Hospital, China

Monocyte Chemoattractant Protein-1 Modulates Invasion and Apoptosis of PC-3M Prostate Cancer Cells Via Regulating Expression of VEGF, MMP9 and Caspase-3 Expression of VEGF, MMP9 and Caspase-3

Results of the first-in-human phase I trial assessing the oral selective c-Met inhibitor MSC2156119J (EMD 1214063) in patients with advanced solid tumors

演題番号 : ISO2-3

Falchook Gerald S.:1、Hong David S.:1、Amin Hesham M.:2、Fu Siqing:1、Piha-Paul Sarina Anne:1、Janku Filip:1、Granda J. Gabrielle:2、Zheng Hongxia:3、Klevesath Manfred B.:4、Koehler Karola:5、Bladt Friedhelm:4、Johne Andreas:6、Kurzrock Razelle:7

1:Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), MD Anderson Cancer Center, Houston, TX, USA、2:Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA、3:Global Research and Early Development, EMD Serono, Boston, MA, USA、4:Merck KGaA, Translational Innovation Platform Oncology, Global Research & Development, Darmstadt, Germany、5:Premier Research Germany Ltd, Biostatistics, Darmstadt, Germany、6:Merck KGaA, Clinical Pharmacology, Darmstadt, Germany、7:University of California San Diego Moores Cancer Center, San Diego, CA, USA

Results of the first-in-human phase I trial assessing the oral selective c-Met inhibitor MSC2156119J (EMD 1214063) in patients with advanced solid tumors

Ubiquitin Ligase Inhibitor is an Effective Combination Therapy with Radiation in Hypoxic Colorectal Cancer Cells

演題番号 : ISO2-4

Gombodorj Navchaa:1、Yoshiyama Shnji:2、Rokudai Susumu:2、Nishiyama Masahiko:2、Nakano Takashi:1

1:Radiation Oncology, Graduate School, Gunma University、2:Molecular Pharmacology and Oncology, Graduate School, Gunma University

Ubiquitin Ligase Inhibitor is an Effective Combination Therapy with Radiation in Hypoxic Colorectal Cancer Cells

A novel anti-cancer agent of DNA-alkylating Pyrrole-Imidazole polyamide conjugate targeting KRAS Codon 12 Mutant DNA

演題番号 : ISO2-5

Nagase Hiroki:1、Hiraoka Kiriko:1、Inoue Takahiro:1、Watanabe Takayoshi:1、Koshikawa Nobuko:1、Yoda Hiroyuki:1、Shinohara Ken-Ichi:1、Ozaki Toshinori:1

1:Cancer Genetics, Chiba Cancer Center

A novel anti-cancer agent of DNA-alkylating Pyrrole-Imidazole polyamide conjugate targeting KRAS Codon 12 Mutant DNA

Implication of IRSp53 in cell proliferation by interaction with p107 via NPY motif

演題番号 : ISO2-6

Safari Fatemeh:1、Suetsugu Shiro:1

1:Molecular Medicine Cell Biology Lab, Graduate School of Biological Sciences, NAIST, Japan

Implication of IRSp53 in cell proliferation by interaction with p107 via NPY motif